Clinical trial
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
NCT00237211 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2001
- Completion date
- October 31, 2006
- Enrollment
- 31 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
postmenopausal women with advanced breast cancer